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OBJECTIVE—Leukocyte adhesion in retinal microvasuculature
substantially contributes to diabetic retinopathy. Involvement of
the Rho/Rho kinase (ROCK) pathway in diabetic microvascu-
lopathy and therapeutic potential of fasudil, a selective ROCK
inhibitor, are investigated.
RESEARCH DESIGN AND METHODS—Localization of
RhoA/ROCK and Rho activity were examined in retinal tissues of
rats. Impact of intravitreal fasudil administration on retinal
endothelial nitric oxide synthase (eNOS) and myosin phospha-
tase target protein (MYPT)-1 phosphorylation, intercellular adhe-
sion molecule-1 (ICAM-1) expression, leukocyte adhesion, and
endothelial damage in rat eyes were investigated. Adhesion of
neutrophils from diabetic retinopathy patients or nondiabetic
control subjects to cultured microvascular endothelial cells was
quantiﬁed. The potential of fasudil for endothelial protection was
investigated by measuring the number of adherent neutrophils
and terminal transferase-mediated dUTP nick-end labeling–posi-
tive endothelial cells.
RESULTS—RhoA and ROCK colocalized predominantly in reti-
nal microvessels. Signiﬁcant Rho activation was observed in
retinas of diabetic rats. Intravitreal fasudil signiﬁcantly increased
eNOS phosphorylation, whereas it reduced MYPT-1 phosphory-
lation, ICAM-1 expression, leukocyte adhesion, and the number
of damaged endothelium in retinas of diabetic rats. Neutrophils
from diabetic retinopathy patients showed signiﬁcantly higher
adhesion to cultured endothelium and caused endothelial apo-
ptosis, which was signiﬁcantly reduced by fasudil. Blockade of
the Fas-FasL interaction prevented endothelial apoptosis. The
protective effect of fasudil on endothelial apoptosis was signiﬁ-
cantly reversed by N-nitro-L-arginine methyl ester, a NOS inhib-
itor, whereas neutrophil adhesion remained unaffected.
CONCLUSIONS—The Rho/ROCK pathway plays a critical role
in diabetic retinal microvasculopathy. Fasudil protects the vas-
cular endothelium by inhibiting neutrophil adhesion and reduc-
ing neutrophil-induced endothelial injury. ROCK inhibition may
become a new strategy in the management of diabetic retinopa-
thy, especially in its early stages. Diabetes 58:215–226, 2009
D
iabetic retinopathy, a prevalent complication
of diabetes, is a leading cause of vision loss
(1). Early nonproliferative stages of diabetic
retinopathy are characterized by retinal mi-
crovascular damage that leads to vascular hyperperme-
ability. Although visual acuity is rarely affected in this
early stage, progression of the diseased states leads to
proliferative retinopathy that can cause severe vision
loss. Vitreous hemorrhage caused by a rupture of neo-
vascular vessels and tractional retinal detachment asso-
ciated with a cicatrical contraction of proliferative
membranes are hallmark of the later diabetic retinopa-
thy stages.
Despite considerable recent advances in vitreoretinal
surgery, generally performed in later diabetic retinopathy
stages, a satisfying visual acuity cannot be always
achieved. Even in the early diabetic retinopathy stages
that might be detected by routine eye exams, management
of general factors, such as blood glucose level (2) and
blood pressure (3), currently constitute the only preven-
tive measures. New approaches for amelioration and treat-
ment of diabetic retinopathy, especially in the earlier
stages, are thus urgently needed.
The various clinical ﬁndings in the retinal vasculature
throughout diabetic retinopathy, such as capillary occlu-
sion and leakage, are related to endothelial damage sec-
ondary to increased leukocyte adhesion at least in part
(4,5). Diabetic leukocyte adhesion in retinal microvessels
is mediated by adhesion molecules, including intercellular
adhesion molecule-1 (ICAM-1) and leukocyte 2-integrins
(CD18/CD11a and CD18/CD11b) (6). In experimental dia-
betes, the expressions of these molecules are increased,
and their blockade prevents leukocyte adhesion and en-
dothelial damage (7). The interaction of endothelial Fas
with Fas ligand (FasL), expressed on adherent neutro-
phils, causes endothelial damage and apoptosis in exper-
imental diabetes (8). However, the role of the Fas/FasL
pathway in human diabetic microvasculopathy remains to
be investigated.
Rho/Rho kinase (ROCK) pathway plays an important
role in pathological vascular conditions, such as cerebral
and coronary spasm (9), hypertension (10), and arterio-
sclerosis (11). Fasudil, a potent and selective ROCK inhib-
itor, is relatively safe and effective in the treatment of
cardiovascular disease (12). Recent studies have shown
that the Rho/ROCK pathway is also involved in the patho-
genesis of diabetes complications in rat renal cortex (13)
and aorta (14). In vitro, Rho activity is increased in bovine
aortic endothelial cells treated with high glucose (15).
Rho/ROCK pathway promotes leukocyte adhesion to the
microvasculature by affecting the expression and function
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DIABETES, VOL. 58, JANUARY 2009 215of adhesion molecules. For instance, Rho/ROCK activation
increases ICAM-1 expression (16). In addition, Rho/ROCK
signaling is associated with ICAM-1 clustering (17) and
activation of ezrin, radixin, and moesin in endothelial
cells, which jointly form the anchoring structures for
leukocyte integrins (18,19). Activation of the Rho/ROCK
pathway stimulates phosphorylation of myosin regulatory
light chain (MLC) (20), causing ﬁrm adhesion of leuko-
cytes to the microvasculature by promoting the higher
afﬁnity state of integrins (21) and their assembly (22).
Endothelial nitric oxide (NO) synthase (eNOS) gener-
ates NO, a potent vasodilator (23) and antiapoptotic factor
(24,25). eNOS expression and function through phosphor-
ylation is decreased in diabetic rat aorta (26) and myocar-
dium (27). In vitro, eNOS phosphorylation is also reduced
by high glucose in coronary artery endothelial cells (28) or
bovine aortic endothelial cells (29). Because Rho/ROCK
activation dephosphorylates eNOS in human umbilical
venous cells (30), we hypothesize that ROCK inhibition
may be antiapoptotic in retinal endothelium during
diabetes.
In the present study, we investigate the mechanisms of
endothelial damage in diabetic microvasculopathy using
neutrophils from diabetic patients. We reveal the critical
role of Rho/ROCK pathway in retinal microvascular dam-
age associated with diabetes. Moreover, we examine the
potential beneﬁt of fasudil as a therapeutic agent in
amelioration and treatment of diabetes-induced microvas-
cular damage especially in the early diabetic retinopathy
stages.
RESEARCH DESIGN AND METHODS
Anti-RhoA mouse monoclonal antibody (mAb), anti-ROCK1 (sc-5561), ROCK2
(sc-5561) rabbit polyclonal antibody (pAb), and anti-CD34 mAb were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa Fluor 488–conjugated
anti-rabbit pAb and anti-mouse pAb, Alexa Fluor 555–conjugated anti-mouse
pAb, and DAPI were obtained from Molecular Probes (Eugene, OR). For ﬂow
cytometry, anti-rat mAbs (CD11a, CD11b, CD18, and FasL) were purchased
from BD PharMingen (San Diego, CA). Anti-human mAbs (CD11a, CD11b, and
CD18) were from BD PharMingen except for anti-FasL (eBioscience, San
Diego, CA). Recombinant human tumor necrosis factor- (rhTNF-) was
purchased from Sigma (Tokyo). Fasudil, a potent and selective ROCK
inhibitor, was a gift of Asahi Kasei Pharma (Tokyo).
Immunoﬂuorescence microscopy. Parafﬁn-embedded sections were dehy-
drated and subsequently incubated with antibodies against RhoA, ROCK1, and
ROCK2. After washing, sections were incubated with Alexa Fluor 488–
conjugated secondary antibody. For double staining, anti-CD34 mAb and
Alexa Fluor 555–conjugated secondary antibody were used for staining
endothelial cells. Counterstaining of nuclei was performed with DAPI. Stain-
ing was observed under a ﬂuorscence microscope (BZ-9000; KEYENCE,
Osaka, Japan).
Animal procedure. Wistar rats (male, 4 weeks) were obtained from Kyudo
(Fukuoka, Japan). The procedures adhered to the guidelines from the
Association for Research in Vision and Ophthalmology for animal use in
research. Each rat received single 65 mg/kg i.p. injections of streptozotocin
(STZ; WAKO, Tokyo). Rats with blood glucose levels 400 mg/dl 24 h after
STZ injection were considered diabetic.
Intravitreal injections were carried out as previously described (31).
Fasudil was dissolved in intraocular irrigating solution (OpeguardMA, Senju
Pharmaceutical, Osaka, Japan). Intravitreal injections of fasudil (5 l, 360
mol/l) were performed over a period of 1 min with a 33-gauge needle on a
Hamilton syringe (Hamilton, Reno, NV) every 3 days after diabetes onset.
Assuming a vitreous humor volume of 60 l, the calculated ﬁnal intraocular
concentration of fasudil was 30 mol/l. Sham injections (Opeguard) were
performed in normal control and diabetic rats. All animals were killed 2 weeks
after diabetes induction.
Rho activity in the retina. GTP bound Rho (Rho-GTP) was examined to
evaluate Rho activity in the rat retinal tissues. Rho activity in control and
diabetic retinas was measured using a Rho activation assay kit (Upstate
Biotechnology, Lake Placid, NY). Whole retinal lysates were extracted
from one eye (60 g protein) per each condition. Total protein concen-
trations were measured and the same amounts of protein were applied in
each sample. Rho-GTP bound to rhotekin-agarose was detected by Western
blotting with anti-Rho mAb, according to the manufacturer’s protocol.
Myosin phosphatase target protein-1 and eNOS phosphorylation. Reti-
nal lysates for Western blotting were prepared as previously described (32).
The blots were blocked with skim milk and incubated overnight at 4°C with
rabbit phospho-myosin phosphatase target protein (MYPT)-1 (1:1,000; Thr853;
CycLex, Nagano, Japan) or rabbit phospho-eNOS (1:1,000; Ser1177; Cell
Signaling, Beverly, MA) and horseradish peroxidase-labeled goat anti-rabbit
IgG (1:4,000; Bio-Rad, Richmond, CA) for1ha troom temperature. Visualiza-
tion was performed with an enhanced chemiluminesence detection system
(Amersham, Arlington Heights, IL). The membranes were also reblotted with
rabbit anti–MYPT-1 (1:2,000; Cell Signaling) and rabbit anti-eNOS (1:1,000;
sc-654; Santa Cruz Biotechnology).
Lane loading differences were normalized by reblotting the membranes
with an antibody against glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Signal intensities were expressed as percentage ratios of phospho–
MYPT-1/GAPDH or phospho-eNOS/GAPDH.
Blood processing and neutrophil isolation. This study was approved by
the institutional review board and performed in accordance with the ethical
standards of the 1989 Declaration of Helsinki. Written informed consents were
obtained from participants. Patients were type 2 diabetic individuals with
diabetic retinopathy, who had undergone vitrectomy because of macular
edema or proliferative changes. Neutrophils were isolated from whole blood
as previously described (33). The purity of neutrophils was 96%, as con-
ﬁrmed by Giemsa staining. Cells were resuspended in RPMI 1640 (Sigma) with
5% fetal bovine serum and used immediately for experiments.
ICAM-1 enzyme-linked immunosorbent assay. ICAM-1 concentration in
the retinal lysates was measured by ELISA (R&D Systems, Minneapolis, MN).
To normalize the ICAM-1 protein levels, total protein concentrations were
measured using the bicinchoninic acid kit (Bio-Rad, Hercules, CA).
Flow cytometry. To quantify CD11a, CD11b, CD18, and FasL expressions on
the surface of neutrophils, the cells were incubated with CD11a mAb (1:50),
CD11b mAb (1:50), CD18 mAb (1:50), and FasL mAb (1:25), which were
labeled with ﬂuorescein isothiocyanate (FITC), phycoerythrin, or biotin. To
detect biotinylated mAbs, allophycocyanin-coupled streptavidin was used as
the secondary reagent (1:50; BD PharMingen). Neutrophils were then washed
with staining buffer, and surface ﬂuorescence of 10
5 cells was analyzed with
a FACSscan (Becton Dickinson, San Jose, CA). Results are expressed as
ﬂuorescence intensity on a logarithmic scale.
Leukocyte adhesion to retinal vasculature. Retinal vessels and adhering
leukocytes in control and diabetic animals were labeled with FITC-conjugated
concanavalin A lectin (ConA; Vector Laboratories, Burlingame, CA), as
previously described (4,34). Brieﬂy, rats were perfused with 50 ml PBS for
5–10 min to remove intravascular content, including erythrocytes and nonad-
herent leukocytes. To allow drainage, a 16-gauge needle was placed into the
right atrium. The perfusion was continued with FITC-coupled ConA (40 g/ml
in PBS). Retinal ﬂat-mounts were prepared for evaluation of leukocyte
accumulation. The total number of adherent leukocytes per retina was
counted using a ﬂuorescence microscope.
Endothelial damage in rat retinas. Dead or injured endothelial cells in rat
retinas were visualized by in vivo staining with propidium iodide (Molecular
Probes) (4,8). Propidium iodide (1 mg/ml) and DAPI (10 mg/ml) were injected
intravenously via femoral vein. After 12 h, the vasculature and adherent
leukocytes in rat retinas were labeled with ConA. The retinas were then
studied under a ﬂuorescence microscope. The total number of propidium
iodide–positive cells per retina was counted.
Neutrophil endothelial adhesion assay. The adhesive property of periph-
eral blood neutrophils, isolated from diabetic retinopathy patients or normal
subjects, to conﬂuent monolayers of human dermal microvascular endothelial
cells (HMVECs; Cambrex, East Rutherford, NJ) was evaluated using an
established coculture system (7). After pretreatment with 0, 5, or 20 mol/l
fasudil for 1 h at 37°C, HMVECs were treated with 10 ng/ml rhTNF- for 12 h
at 37°C in humidiﬁed 5% CO2 atmosphere to enhance leukocyte adhesion.
Neutrophils were resuspended at 10
6 cells/ml and labeled with 1 mmol/l
Calcein-AM (BD PharMingen) for 30 min at 37°C in RPMI 1640. Labeled
neutrophils were washed and coincubated (20  10
4 cells/ml, 500 l per well)
with pretreated HMVECs for1ha t37°C. Nonadherent cells were washed out,
and the number of adherent neutrophils in four different areas of each well
was counted and averaged using Image J software (NIH).
Endothelial apoptosis induced by adherent neutrophils. HMVECs were
incubated for 10 min with Hoechst 33342 (red ﬂuorescence). After pretreat-
ment with fasudil for 1 h, HMVECs were stimulated for 12 h with 10 ng/ml
rhTNF- at 37°C. Unlabeled neutrophils (50  10
4cells/ml) were cocultured
with HMVEC for 12 h at 37°C as described above. Apoptotic and potentially
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mediated dUTP nick-end labeling (TUNEL) staining with the TdT ﬂuorescein
in situ apoptosis detection kit (R&D Systems), according to the manufactur-
er’s protocol. Apoptotic HMVECs demonstrated double labeling and appeared
yellow. The number of apoptotic cells in four different areas per well was
counted using ﬂuorescence microscopy.
To determine the involvement of NO and Fas/FasL signaling in endothelial
apoptosis, HMVECs were preincubated with 1 mmol/l N-nitro-L-arginine
methyl ester (L-NAME; Sigma), an inhibitor of NOS, before fasudil treatment,
and neutrophils were incubated with soluble Fas receptor (sFasR; Kamiya
Biomedical, Seattle, WA), which inhibits FasL-induced apoptosis by acting as
a decoy receptor, before coculture for1ha t37°C. To investigate the
involvement of Rho/ROCK pathway in Fas/FasL signaling, HMVECs were
preincubated with fasudil in the presence or absence of L-NAME before the
addition of soluble FasL (Sigma) for1ha t37°C.
Statistical analysis. All results were expressed as means  SE. Statistical
differences were assessed using the nonparametric Kruskal-Wallis variance
analysis. To adjust for inﬂated  errors due to multiple comparisons, the
corrected signiﬁcant P value was deﬁned using the Bonferroni correction.
Statistical differences between two groups were analyzed by Mann-Whitney U
test.
RESULTS
Rho/ROCK activation in retinal vessels during diabe-
tes. To investigate the localization of RhoA, ROCK1, and
ROCK2, we harvested rat retinal tissue and performed
immunohistochemistry. These proteins were mainly ex-
pressed in retinal vessels, because endothelial and vascu-
lar smooth muscle cells exhibited positive staining (Fig.
1A–C).
In addition, the levels of activated Rho (	-GTP) were
signiﬁcantly higher in the diabetic rat retinas, compared
with those in nondiabetic controls (1.31-fold, P 
 0.01, n 
5 each) (Fig. 1D and E).
ROCK suppression in the retina by fasudil. Two weeks
after diabetes onset, diabetic rats showed signiﬁcant
weight loss compared with the nondiabetic controls (non-
diabetic [n  15], 346  21 g vs. diabetic [n  15], 253 
15 g, P 
 0.01). Fasudil treatment did not affect the
diabetic weight loss (n  15, 266  6 g, NS). The average
blood glucose levels (446  13 mg/dl) in diabetic rats were
signiﬁcantly higher compared with those of nondiabetic
rats (127  21 mg/dl, P 
 0.01), and fasudil treatment did
not affect diabetic rat blood glucose levels (460  26
mg/dl).
To examine the efﬁcacy of fasudil for ROCK inhibition in
the retina, we quantiﬁed the amount of phosphorylated
MYPT-1 and eNOS, downstream targets of ROCK. In line
with our Rho activity data (Fig. 1D and E), MYPT-1
phosphorylation was markedly increased in the retinas of
vehicle-treated diabetic rats, compared with the vehicle-
treated nondiabetic controls (2.7-fold, n  6 each, P 

0.01). In comparison, treatment with fasudil in diabetic
rats signiﬁcantly reduced the increase of phosphorylated
MYPT-1 by 72% (n  6 each, P 
 0.01) (Fig. 2B).
In addition, eNOS and eNOS phosphorylation in the
retinas of vehicle-treated diabetic rats were downregu-
lated by 35 and 57%, respectively, compared with vehicle-
treated nondiabetic controls (n  6 each, P 
 0.01).
Fasudil treatment almost completely reversed the de-
creased eNOS expression and phosphorylation in diabetic
rat retinas (n  6 each, P 
 0.01; Fig. 2C and D).
Suppression of diabetes-induced retinal leukocyte
adhesion by fasudil. The mean ﬂuorescence of CD11b
(753  209) and CD18 (369  52) on diabetic rat
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FIG. 1. Localization and activity of Rho/ROCK in retinal vessels. Parafﬁn-
embedded sections of nondiabetic rat retinas were immunohistochemi-
cally analyzed with RhoA (A), ROCK1 (B), and ROCK2 (C) antibodies
(magniﬁcation 400). Endothelial cells were stained with rhodamin-
conjugated anti-CD34 (red). RhoA, ROCK1, and ROCK2 were detected by
green ﬂuorescence. Yellow (white arrowhead) indicates double-stained
vasculature. D: Representative blot showing the level of -GTP in nondi-
abetic control or STZ-induced diabetic rat retinas detected by Rho
pull-down assay. E: Average signal intensities quantiﬁed and expressed
as percentage of the ratio of control (**P < 0.01, n  5 each). (Please see
http://dx.doi.org/10.2337/db08-0762 for a high-quality digital representa-
tion of this ﬁgure.)
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mal controls (135  24, P 
 0.01, and 176  25, P 
 0.01,
respectively, n  8 each). However, the mean ﬂuores-
cence intensity of CD11a in neutrophils of diabetic
animals (1,170  161) did not differ signiﬁcantly from
that of normal controls (1,049  63, n  8 each, NS)
(Fig. 3A–F).
Furthermore, in diabetic retinas, ICAM-1 expression
was signiﬁcantly elevated compared with nondiabetic con-
trols (1.21-fold, P 
 0.01, n  7 each; Fig. 3G). The number
of ﬁrmly adhering leukocytes in retinas of the diabetic
animals was 3.8-fold higher than in the nondiabetic con-
trols (n  7 each, P
0.01; Fig. 3H and I). ROCK inhibition
by intravitreal fasudil injection signiﬁcantly reduced
ICAM-1 expressions in the diabetic retinas by 83% of the
increase in vehicle-treated diabetic controls compared
with the vehicle-treated nondiabetic controls (n  7 each,
P 
 0.01; Fig. 3G). Furthermore, the diabetes-induced
leukocyte adhesion to retinal vasculature was signiﬁcantly
suppressed by 68% in fasudil-treated animals (n  7 each,
P 
 0.01; Fig. 3H and I). Leukocyte adhesion in vehicle-
treated rats did not signiﬁcantly differ from that in un-
treated control rats (n  7 each; Fig. 3H and I). Integrin
expressions in fasudil-treated diabetic animals did not
signiﬁcantly differ from those of vehicle-treated diabetic
rats (n  8 each; Fig. 3A–F).
Prevention of neutrophil-induced retinal endothelial
damage in diabetic animals by fasudil. The expression
of FasL, an apoptosis-inducing factor, on the surface of the
peripheral blood neutrophils from diabetic animals (553 
47, n  8) was signiﬁcantly higher compared with that
from nondiabetic controls (207  20, P 
 0.01, n  8).
Intravitreal injection of fasudil did not signiﬁcantly change
the expressions of FasL on peripheral blood neutrophils
(Fig. 4A and B).
In vivo, the number of propidium iodide–positive in-
jured or dead endothelial cells per retina was signiﬁcantly
increased by 8.1-fold in diabetic rats compared with the
nondiabetic controls (n  5 each, P 
 0.01). In the
fasudil-treated diabetic animals, the number of propidium
iodide–positive cells in the retina showed a signiﬁcant 94%
reduction of the increase in the vehicle-treated diabetic
controls (P 
 0.01), whereas the number of propidium
iodide–positive cells in vehicle-treated rats did not signif-
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FIG. 2. Impact of intravitreal fasudil on retinal ROCK activity. Phosphory-
lated MYPT-1 (Thr853) and eNOS (Ser1177) were detected in rat retinal
preparations by Western blot analysis. Lane loading differences were
normalized by reblotting the membranes with an antibody against GAPDH.
A: Representative results of phospho-MYPT-1 and GAPDH in rat retinas. B:
ROCK activity was expressed as the ratio of phospho-MYPT-1 to GAPDH
(**P < 0.01, NS; n  6 each). C: Representative results of phospho-eNOS
and GAPDH. D: Average signal intensities quantiﬁed and expressed as
percentage of the ratio of control (**P < 0.05, NS; n  6 each).
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and D).
Reduced adhesion of human diabetic neutrophils to
HMVECs by fasudil. The mean ﬂuorescence of CD18
(69  11, P 
 0.05 vs. control) and CD11b (266  60, P 

0.05 vs. control) in neutrophils of diabetic retinopathy
patients was signiﬁcantly higher than in nondiabetic
controls (CD18 [45  9] and CD11b [118  31], respec-
tively). CD11a expression in neutrophils of diabetic
retinopathy patients (363  58) did not signiﬁcantly
0
5
10
15
20
25
30
35
40
45
50
diabetes
N.S.
**
N.S.
**
N.S.
A
B
C
D
E
F
N.S.
M
e
a
n
 
f
l
u
o
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
M
e
a
n
 
f
l
u
o
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
M
e
a
n
 
f
l
u
o
r
e
s
c
e
n
c
e
 
i
n
t
e
n
s
i
t
y
I
C
A
M
-
I
 
p
r
o
t
e
i
n
(
p
g
/
m
g
 
t
o
t
a
l
 
r
e
t
i
n
a
l
 
p
r
o
t
e
i
n
)
6
8
10
12
14
16
18
**
G
**
H
I
n
u
m
b
e
r
 
o
f
 
a
d
h
e
r
e
n
t
 
l
e
u
k
o
c
y
t
e
s
/
r
e
t
i
n
a ** **
diabetes
fasudil: (-) (+) (-) (+)
fasudil
(-) (+) (-) (+) fasudil: (-) (+) (-) (+)
diabetes
fasudil: (-) (+) (-) (+) fasudil:
diabetes + fasudil diabetes + vehicle non-diabetes+ vehicle
N.S.
vehicle
N.S.
N.S.
(cell)
untreated fasudil vehicle untreated
0
200
400
600
800
1000
1200
0
50
100
150
200
250
300
350
400
450
diabetes diabetes
0
200
400
600
800
1000
1200
1400
1600
1800
2000
1500
1000
500
0
100 101 102 103
#
 
C
e
l
l
s
2500
2000
1500
1000
500
0
100 101 102 103
#
 
C
e
l
l
s
2500
2000
1500
1000
500
0
100 101 102 103
#
 
C
e
l
l
s
FIG. 3. Reduction of diabetes-induced retinal leukocyte adhesion by fasudil. Intravitreal injections of fasudil at 0 mol/l (vehicle) or 30 mol/l
(ﬁnal vitreal concentration) were performed every 3 days for 2 weeks. Cell surface expressions of CD11a (A), CD11b (C), and CD18 (E)o n
nondiabetic control (thin line) and diabetic rat neutrophils (thick line) were analyzed by ﬂow cytometry. Mean ﬂuorescence intensity of
CD11a (B), CD11b (D), and CD18 (F) (**P < 0.01, NS; n  8 each; dotted line, mouse isotype control). G: Retinal ICAM-1 concentrations
measured by enzyme-linked immunosorbent assay in retinas of normal and diabetic animals with and without fasudil treatment (**P < 0.01,
n  7 each). H: Representative ConA-stained ﬂat mounts of normal and diabetic animals with and without fasudil treatment. White
arrowhead, ﬁrmly adhering leukocytes. I: Quantitative analysis of the number of ﬁrmly adhering leukocytes in normal and diabetic rats with
and without fasudil treatment (**P < 0.01, NS; n  7 each). (Please see http://dx.doi.org/10.2337/db08-0762 for a high-quality digital
representation of this ﬁgure.)
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(405  50) (n  20 each, Fig. 5A–F).
The number of diabetic retinopathy neutrophils that
bound to HMVECs was 1.9-fold higher than that of the
nondiabetic controls (n  15, P
0.01). Fasudil signiﬁ-
cantly reduced diabetic retinopathy patients’ neutrophil
adhesion in a dose-dependent manner (38% reduction at 5
mol/l, P 
 0.01; 63% reduction at 20 mol/l, n  15 each,
P 
 0.01). However, the adhesion of peripheral blood
neutrophils from nondiabetic controls was not signiﬁ-
cantly affected with fasudil treatment (20 mol/l: 45%
reduction, n  15, vs. without fasudil; Fig. 5G and H).
Role of Fas/FasL in neutrophil-induced endothelial
apoptosis. To elucidate mechanisms of immune cell–
mediated vascular injury during diabetes, we measured
the expression of FasL on the surface of peripheral
blood neutrophils from diabetic retinopathy patients
and nondiabetic controls by ﬂow cytometry. The mean
ﬂuorescence of FasL (8.6  1.6) on diabetic retinopathy
neutrophils was signiﬁcantly higher than that of nondi-
abetic controls (4.2  0.5, n  17 each, P 
 0.01) (Fig.
6A and B).
Endothelial apoptosis, induced by diabetic retinopathy
neutrophils, was signiﬁcantly inhibited by sFasR, which
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FIG. 4. Prevention of neutrophil-induced ret-
inal endothelial damage by fasudil. A: Cell
surface expressions of FasL on nondiabetic
control (thin line) and diabetic (thick line)
rat neutrophils were analyzed by ﬂow cytom-
etry. B: Average mean ﬂuorescence intensity
of FasL on peripheral blood neutrophils from
normal and diabetic rats with and without
intravitreal fasudil injection (**P < 0.01, NS;
n  8 each; dotted line, mouse isotype con-
trol). C and D: In vivo visualization of dead or
injured endothelial cells (red, propidium io-
dide [PI]) and endothelial nuclei (blue, DAPI)
in rat retinas. Propidium iodide–positive cells
(white arrowhead) widely coincided with ad-
herent leukocytes (white arrow). The number
of propidium iodide–positive cells per retina
was signiﬁcantly higher in the diabetic ani-
mals compared with the nondiabetic controls.
Fasudil caused a signiﬁcant reduction in the
number of propidium iodide–positive cells in
the retinas of the diabetic animals compared
with the vehicle-treated controls (**P < 0.01,
NS; n  5 each). (Please see http://dx.doi.org/
10.2337/db08-0762 for a high-quality digital
representation of this ﬁgure.)
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dose-dependent manner up to 10 g/ml (n  5 each, P 

0.01; Fig. 6C and D).
Prevention of sFasL or neutrophil-induced endothe-
lial apoptosis by fasudil. HMVEC incubation with con-
trol or diabetic retinopathy neutrophils signiﬁcantly
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FIG. 5. Reduced adhesion of neutrophils from diabetic retinopathy patients to HMVECs by fasudil. Cell surface expressions of CD11a (A), CD11b
(C), and CD18 (E) on neutrophils from nondiabetic control subjects (thin line) and those with diabetic retinopathy (DR) (thick line) were
analyzed by ﬂow cytometry. Mean ﬂuorescence intensity of CD11a (B), CD11b (D), CD18 (F)( * P < 0.05, NS; n  20 each; dotted line, mouse
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counted and averaged (**P < 0.01, NS; n  15 each).
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(control neutrophils, 9.8  2.7cells/mm
2, n  15, P 
 0.01;
diabetic retinopathy neutrophils, 33.2  8.0 cells/mm
2, n 
15, P 
 0.01 vs. no neutrophils, respectively; Fig. 7A and
B). Treatment of the diabetic retinopathy neutrophils
with fasudil signiﬁcantly decreased endothelial apopto-
sis in a dose-dependent fashion (diabetic retinopathy
neutrophils with fasudil at 5 mol/l, 17.9  6.9cells/
mm
2, P 
 0.01 or at 20 mol/l, 6.1  1.4 cells/mm
2, P 

0.01, vs. without fasudil, respectively, n  15 each; Fig.
7A and B).
Incubation of HMVECs with sFasL signiﬁcantly in-
creased the number of endothelial apoptosis (with sFasL,
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FIG. 6. Fas/FasL-mediated endothelial apoptosis by adherent neutrophils. A: Cell surface expressions of FasL on neutrophils from nondiabetic
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2), which was signiﬁcantly reduced by fasudil
treatment (sFasL with fasudil, 6.0  2.2 cells/mm
2, P 

0.01 vs. sFasL alone, n  4 each; Fig. 7C and D).
Protective role of NO in neutrophil-induced endothe-
lial apoptosis. L-NAME, a broad inhibitor of NOSs, signif-
icantly reversed the effect of fasudil on sFasL-induced
FIG. 7. Prevention of neutrophil-induced endothelial apoptosis by fasudil. A and B: After pretreatment with 0, 5, or 20 mol/l fasudil for 1 h,
HMVECs were stimulated for 12 h with 10 ng/ml rhTNF-. Subsequently, unlabeled neutrophils (5  10
5cells/ml) were cocultured with HMVECs
for 12 h. Scale bar  100 m. The number of apoptotic cells (yellow ﬂuorescence) in four different areas per well was counted (**P < 0.01, NS;
n  15 each). C and D: Involvement of fasudil in sFasL-induced apoptosis was investigated. HMVECs were preincubated with or without 20 mol/l
fasudil before sFasL treatment for 1 h. Furthermore, HMVECs were incubated with or without 1 mmol/l L-NAME before fasudil treatment for 1 h.
Scale bar  100 m. The number of TUNEL-positive cells in four different areas per well was counted and averaged (**P < 0.01, NS; n  4 each).
(Please see http://dx.doi.org/10.2337/db08-0762 for a high-quality digital representation of this ﬁgure.)
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 0.01, n  4 each; Fig. 7C and
D). L-NAME did not affect the fasudil-induced decrease in
the number of patient neutrophil binding to the endothelial
cells compared with diabetic retinopathy neutrophils with-
out L-NAME (n  10 each, NS; Fig. 8A). However, the
protective effect of fasudil on endothelial apoptosis was
signiﬁcantly reversed by L-NAME compared with diabetic
retinopathy neutrophils without L-NAME (n  10 each,
P 
 0.01; Fig. 8B).
DISCUSSION
The rapidly growing prevalence of diabetes necessitates
the development of new therapeutic strategies for diabetic
retinopathy, a blinding complication of the disease. This
work introduces the role of Rho/ROCK pathway in the
diabetic retinal microvascular damage. We demonstrate
the therapeutic potential of fasudil, a potent and selective
ROCK inhibitor, as a novel pharmacological strategy in
early diabetic retinopathy treatment.
Our results show colocalization of RhoA and ROCK
predominantly in retinal microvessels. We found enhanced
levels of 	-GTP and phosphorylated MYPT-1, a down-
stream mediator of ROCK, in retinas of diabetic rats,
demonstrating the activation of the Rho/ROCK pathway in
retinal microvessels during diabetes. These ﬁndings sug-
gest involvement and elevated activity of the Rho/ROCK
pathway in the pathogenesis of diabetic microvasculopa-
thy. We thus investigated whether the inhibition of this
pathway might be beneﬁcial in amelioration or treatment
of diabetic microvascular damage.
Fasudil is a selective ROCK inhibitor with minimal
effects on other pathways, such as MLC kinase or protein
kinase C (35). Our recent experiments have conﬁrmed that
repeated intravitreal injections of fasudil at a ﬁnal concen-
tration of 30 mol/l in rabbit eyes and single intravitreal
injection of fasudil up to 100 mol/l in rat eyes did not
cause apparent electrophysiological or morphological
changes in retinal tissues or induction of inﬂammatory
cells, compared with the untreated control eyes (36).
Intravitreal injection of vehicle also did not cause signiﬁ-
cant leukocyte adhesion or endothelial damage in rat
retinas, compared with untreated control. We demon-
strated its efﬁcacy for retinal ROCK inhibition after intra-
vitreal injection, measured by MYPT-1 phosphorylation.
Our investigations of the impact of fasudil on diabetic
leukocyte adhesion showed, in line with previous reports,
elevated retinal ICAM-1 (34,37) and increased CD18/
CD11b expression on peripheral blood neutrophils (7) of
the diabetic animals. These ﬁndings indicate higher adhe-
sive properties of both neutrophils and the vascular endo-
thelium during diabetes. We further provide evidence that
intravitreal injection of fasudil effectively suppresses the
increased ICAM-1 expression and retinal leukocyte adhe-
sion in diabetic animals. However, it appears that the
dramatic effect of fasudil in reducing diabetic leukocyte
adhesion may be not solely explained by the reduction of
ICAM-1 expression. In addition to ICAM-1 expression, it is
possible that fasudil may affect ICAM-1 clustering and
assembly, because clustering (17) and assembly (18,19) of
ICAM-1 at focal adhesion sites are critical for the mole-
cule’s afﬁnity. Fasudil also dilates retinal vessels and
increases blood ﬂow (10). Therefore, it is feasible that the
reduction of the retinal leukocyte adhesion in fasudil-
treated diabetic animals could be in part due to improved
hemodynamics in the retinal vessels.
Our experiments furthermore conﬁrmed that the endo-
thelial damage in retinas of diabetic animals is widely
associated with leukocyte adhesion. In line with previous
reports, we found elevated FasL expression on peripheral
blood neutrophils in diabetic rats (8), suggesting that
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FIG. 8. Prevention of neutrophil-induced endothelial apoptosis by fasudil. After pretreatment with 0 or 20 mol/l fasudil for 1 h, HMVECs were
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during diabetes via Fas/FasL signaling. Moreover, fasudil
effectively suppressed endothelial damage, even when
leukocytes ﬁrmly adhered to the endothelium. As a possi-
ble mechanism, in addition to attenuating retinal leuko-
cyte adhesion, the restored eNOS phosphorylation in rat
retina by fasudil might contribute to the prevention of
leukocyte-induced endothelial damage.
To further elucidate the mechanisms of leukocyte-in-
duced endothelial damage and protective effect of fasudil,
we investigated the adhesion and proapoptotic effects of
human neutrophils from normal subjects and diabetic
retinopathy patients on the microvascular endothelium in
vitro.
Similar to diabetic rats, the expressions of adhesion
molecules on neutrophils from diabetic retinopathy pa-
tients were remarkably increased, compared with nondia-
betic control subjects. In this study, we used TNF- to
enhance neutrophil adhesion and neutrophil-induced en-
dothelial apoptosis in the diabetic coculture assay, be-
cause TNF- has been implicated in the pathogenesis of
diabetic microvascular damage (38–40) and diabetic reti-
nopathy (40,41).
Compared with nondiabetic neutrophils, diabetic reti-
nopathy neutrophils adhere signiﬁcantly more to the cul-
tured endothelium, which is effectively suppressed by
fasudil treatment. Without neutrophils, only few endothe-
lial cells were found apoptotic. In comparison, neutrophils
from diabetic retinopathy patients caused signiﬁcantly
higher numbers of apoptosis in the endothelium, which
was effectively inhibited by fasudil treatment. Further-
more, diabetic retinopathy neutrophil-induced endothelial
apoptosis was signiﬁcantly reduced by competitive inhibi-
tion of FasL with sFasR, indicating the critical role of
endothelial Fas interaction with FasL on adherent neutro-
phils for apoptosis. This may in part contribute to the
pathogenesis of diabetic microvasculopathy.
The fact that fasudil inhibits neutrophil-induced endo-
thelial apoptosis and sFasL-induced endothelial apoptosis
suggests that the vasculoprotective function of fasudil may
be in part due to inhibition of Fas/FasL signaling, activated
by adherent neutrophils. Our results further suggest that
the protective effect of fasudil on endothelial apoptosis is
likely NO mediated, because it was signiﬁcantly blocked
by NOS inhibition with L-NAME, without apparent effect
on neutrophil adhesion. This suggests that fasudil may
cause direct NO-mediated endothelial protection that is
independent of its impact on neutrophil adhesion. More-
over, we demonstrate that L-NAME reverses sFasL-in-
duced endothelial apoptosis. These observations indicate
that fasudil protects from Fas/FasL-induced endothelial
damage, a process that appears to be NO dependent. In
contrast, previous reports indicate that inducible NO syn-
thase (iNOS) is involved in leukostasis and vascular ab-
normality in STZ mice (42,43). NO can prevent or promote
apoptosis in endothelial cells, dependent on its concentra-
tion and source. Physiological levels of NO, synthesized by
eNOS, contribute to endothelial protection (44,45),
whereas excessive levels of NO, synthesized by overex-
pression of iNOS, promote destruction of endothelial cells
(46). In the retinas of our experimentally diabetic rats,
iNOS expression was not signiﬁcantly changed with or
without fasudil treatment (data not shown). A further
complication is that in vitro and in vivo eNOS expression
in response to high glucose is highly time dependent,
initially increasing (47), but eventually declining (26,48–
50). Our study was performed when eNOS expression in
retinas of diabetic rats was expected to be lower than
baseline levels.
Because the course of retinal changes during diabetes in
rats may differ from that in humans, further studies will be
needed to assess the therapeutic potential and safety of
fasudil in diabetic retinopathy patients. Our data reveal the
critical role of the Rho/ROCK pathway in the pathogenesis
of diabetic retinal microvasculopathy and the therapeutic
potential of the ROCK inhibitor, fasudil, in reducing dia-
betic retinal leukocyte accumulation and endothelial dam-
age. ROCK inhibition might become a novel therapeutic
strategy in the treatment of diabetic retinopathy, espe-
cially in its earlier stages.
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